{'fraction_non_alphanumeric': 0.027479091995221028, 'fraction_numerical': 0.0, 'mean_word_length': 5.5984251968503935, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Determination of adalimumab and etanercept trough levels and drug antibodies in long‐term psoriasis treatment: a single‐centre cohort study

An algorithm based on measurement of a serum tumour necrosis factor antagonists (anti‐TNF) and antidrug antibodies (ADA) has been proposed previously to guide dose escalation or therapy switching in the early (i.e. the first months of) treatment of psoriasis by anti‐TNF. In long‐term treatment of responding patients with psoriasis, it is usual to empirically reduce standard doses of anti‐TNF to reduce exposure while maintaining clinical response. The relationship between serum anti‐TNF, ADA levels and clinical efficacy in long‐term treated patients with psoriasis has not yet been determined, so the potential role of these parameters in guiding dose escalation in this scenario is unknown.